$ABEO News Article - New Positive Phase 1/2 Interim Data Presented at WORLDSymposium(TM) Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona's ABO-102 Gene Therapy
https://marketwirenews.com/news-releases/new-...21547.html